ShowcasesPricing
  1. US-listed companies
  2. Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plcJAZZ

Market cap
$6.8B
P/E ratio
16.4x
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Product sales, net---------2,3473,0793,6413,737
Royalties and contract revenues-------212617151897
Total revenues2725868721,1731,3251,4881,6191,8912,1622,3643,0943,6593,834
Cost of product sales (excluding amortization of acquired developed technologies)---117103105110122128149441541436
Selling, general and administrative1092243044064495035446847378541,4521,4171,343
Research and development---------335506590850
Intangible asset amortization7737912798102152201355260526599608
Asset Impairment Charges---3932--43-136-134-
Acquired in-process research and development---203-2485-110251-44419
Acquired in-process research and development---203-2485-110251-44419
Asset Impairment Charges---3932--43-136-134-
Total operating expenses--------1,6291,9852,9243,7253,256
Income (loss) from operations128198340196508592529615532378170-66579
Interest expense, net--17-27-53-57-62-78-77-72-100-279-288-289
Foreign exchange gain (loss)-----3-10-7-6-3-4-199
Income (loss) before income tax expense (benefit) and equity in loss of investees-----532441529454275-113-373298
Income tax expense (benefit)--849294106135-4880-7334216-159-120
Equity in loss of investees------0-1-2-4-3-1-10-3
Net income (loss)12528921658330397488447523239-330-224415
Earnings Per Share, Basic3.015.093.710.985.386.568.137.459.224.28-5.52-3.586.55
Earnings Per Share, Diluted2.674.793.510.935.236.417.967.39.094.22-5.52-3.586.1